Ginkgo Bioworks Holdings (DNA) stock

Cell programming , market cap $671M

Cell programming and biosecurity services

Worth $671M

$12.01

-2.91%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#95of 281

Biotech

Checks firing

5of 14

Trending up

From 52-week high

-34.1%

under its best in a year

DNA's Quality Score was unchanged on Tue, Nov 10, at 3.

See DNA's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why DNA rose on Nov 6

Up 13% on Nov 6 while the S&P 500 rose 0.3%.

Its Nov 5 results: net loss from continuing operations narrowed to $41M, from $73M a year before. It rose 13% on Nov 6.

Sources: Price history, Nov 6, 2026; Company release, Nov 5, 2026

1 more reason, free with an account →2 more reasons why DNA rose on Nov 6, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on DNA

Key facts on DNA
Since its Nov 2021 high	Down 98% sales $313.8M → $130.8M a year
Latest filing	10-Q, Nov 9 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

1 more reason behind DNA's 3, free with an account →4 more reasons behind DNA's 3, for Pro members.

DNA in the news

Fri Nov 6Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo SEC filing 4:07 PM ET · Business Wire and 1 more DNA closed +13.4% that day.

Outlet counts from the GDELT Project.

DNA catalysts

Coming up

After its last 4 reports it closed -10.0% on average, higher 1 of 4 times.

21 past catalysts since 2022, with sizes and sources, for Pro members.

Why DNA scores 3

Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades subtracts

No effect today: Size, Profit, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on DNA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:13 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when DNA's Quality Score turns up

A free account. No card.

How DNA ranks in Biotech

DNA is #95 of 281 by Quality Score.

How DNA ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	DFTXDefinium Therapeutics		Open for its score
	DMRADamora Therapeutics		Open for its score
	DNLIDenali Therapeutics		Open for its score
	DNTHDianthus Therapeutics		Open for its score
95	DNAGinkgo Bioworks	5/14	3

When does DNA report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DNA reported on Nov 5, 2026

The quarter

Sales of $27.7M, 6% less than a year ago.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

DNA's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total cash burn	($150)-($125) millionkept

Figures as filed (SEC filing, Nov 5)

The numbers

Market value: $671M; today
Sales: $131M; down 13.2% on the year
Free cash flow: -$174M; last 12 months

Sales grew 17% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 9.7% a year over 3 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DNA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-13.5%-9.3%+13.3%

May 7Aug 5Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	+2.0%	+13.3%	not yet
Aug 5, 2026After close	After close	-2.6%	-9.3%	-23.1%
May 7, 2026After close	After close	-16.2%	-13.5%	-23.9%

DNA closed higher after 1 of its last 4 reports.

All 4 reports, and DNA's Quality Score going into each

DNA sales and profit by year

Sales and profit by year

Sales grew in three of the last six years, to $170M in 2025. It lost money in each of the seven years.

DNA has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on DNA, and all 14 on every stock.Get in free →

DNA RSI today: 54.5, above its 50-day and 200-day averages

Not scored

RSI 54.5, MACD above signal, above both averages. Not scored.13 readings

The deep dive on DNA

What it does and how it makes money4 findingsServices made up 22% of its revenue in fiscal 2025 ($37.4M of $170M), against 23% in fiscal 2024; cell engineering revenue 78%.SEC filing · Feb 26, 2026
Where it stands5 findingsFor Pro members5 findings on where DNA stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingBacklog rose 54% in a year, to $126M on Sep 30, 2026 from $81.3M: sales under contract, not yet delivered.Filed figures, Sep 30, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades DNA, for Pro members

11 more findings on DNA, each with its source, for Pro members.

DNA share count over time

Shares: 15.0% more than a year ago (to Sep 30).

Offerings, shelves, and splits of DNA, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 15% of its market value	Sep 4, 2025

DNA insider trades

4 insiders sold $971K across 9 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJason R. Kelly$463KInsiderat $10.14 on Oct 19, filed Oct 21

SellJason R. KellyInsider$463Kat $10.14 on Oct 19, filed Oct 21

All 9 insider filings on DNA from the last six months, for Pro members.

All DNA insider trades

DNA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Steven P. CoenOfficer · 10 trades
Reshma P. ShettyOfficer · 5 trades
Jason R. KellyOfficer · 3 trades
Christian O. HenryDirector · 1 trade

See insider trades by person

Which ETFs hold DNA?

In ETFs: DNA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

485 employeesBoston, MAginkgobioworks.com

What Ginkgo Bioworks Holdings says it competes with

“The services and products offered by potential competitors vary in size, breadth, and scope, and given our broad set of application areas, we could face competition in many different forms.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on DNA and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn DNA's score around: 9 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 21Jason R. Kelly sold DNA$463K at $10.14, filed Oct 21

Alerts are optional.

See DNA's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: DNA's Quality Score is 3 (Below Average), #95 of 281 in Biotech. Insiders sold $971K in the last 6 months (Form 4).

What does DNA's Quality Score say?

DNA scores 3 today, which Breakaway calls Below Average. It is #95 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Up 13% on Nov 6 while the S&P 500 rose 0.3%. Shares: 15.0% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DNA's Quality Score?

DNA scores 3 today, which Breakaway calls Below Average (0 to 5). That is #95 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DNA's 3.

Are insiders buying DNA?

4 insiders sold $971K across 9 filings in the last 6 months. No open-⁠market buys on record. The newest is Jason R. Kelly, Insider, who sold $463K on Oct 19. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.